Catalent Newsroom

RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target

BenzingaJul 11 23:02

Catalent Analyst Ratings

BenzingaJul 11 23:00

Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)

TipRanksJul 11 18:41

Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating

MT NewswiresJun 28 23:55

Catalent Analyst Ratings

BenzingaJun 28 23:43

Barclays Adjusts Catalent Price Target to $63 From $47

MT NewswiresJun 27 19:20

Catalent's Resilient Growth and Positive Outlook Reinforce Buy Rating

TipRanksMay 10 13:45

RBC Capital Sticks to Their Hold Rating for Catalent (CTLT)

TipRanksMay 9 18:49

Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48

MT NewswiresApr 12 22:37

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)

TipRanksApr 12 13:50

Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)

TipRanksApr 5 15:55

Catalent Analyst Ratings

BenzingaApr 4 22:30

Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)

TipRanksMar 5 14:25

RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target

BenzingaFeb 20 23:28

Catalent Analyst Ratings

BenzingaFeb 20 23:25

Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT)

TipRanksFeb 20 20:31

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)

TipRanksFeb 12 21:20

Catalent (CTLT) Gets a Hold From Barclays

TipRanksFeb 12 16:46

Catalent Stock Downgraded Post Novo Nordisk Acquisition Deal

InvestingFeb 8 07:14

Analyst Maintains Hold Rating Amid Catalent's Strategic Acquisition and Complex Valuation

TipRanksFeb 7 21:35